CEL-SCI (NYSE:CVM) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a note issued to investors on Friday. The firm set a “sell” rating on the stock.

CEL-SCI Price Performance

NYSE CVM opened at $0.39 on Friday. The firm has a market capitalization of $29.00 million, a PE ratio of -0.77 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.31 and a quick ratio of 1.09. CEL-SCI has a 12 month low of $0.36 and a 12 month high of $3.08. The company’s 50 day simple moving average is $0.55 and its 200 day simple moving average is $0.90.

Hedge Funds Weigh In On CEL-SCI

A number of institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its holdings in shares of CEL-SCI by 9.6% in the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after purchasing an additional 53,879 shares in the last quarter. Renaissance Technologies LLC raised its position in CEL-SCI by 29.9% during the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock valued at $202,000 after buying an additional 40,000 shares during the period. Calton & Associates Inc. purchased a new stake in CEL-SCI in the 3rd quarter worth about $50,000. Finally, Plotkin Financial Advisors LLC acquired a new stake in CEL-SCI during the 3rd quarter worth about $98,000. Hedge funds and other institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.